Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00286429 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.
A Phase 3 study of Diabetes Mellitus, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 390
- Enrollment target
- 20
- Study locations
NCT00286429: Completed Phase 3 study of Diabetes Mellitus, sponsored by Takeda.
NCT00286429 is a Phase 3 study of Diabetes Mellitus that has completed, run by Takeda. The registered enrollment target is 390 participants, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00286429, a Phase 3 study of Diabetes Mellitus, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 390 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the efficacy and safety of alogliptin, once daily (QD), taken in combination with insulin for the treatment of Type 2 Diabetes.
Primary Outcome
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 26 or final visit and glycosylated hemoglobin collected at baseline.
Conditions Studied
Interventions
- DRUG Insulin
- DRUG Alogliptin and insulin
Study Locations (20)
California
- - Anaheim
- - Artesia
- - Fresno
- - Mission Viejo
- - Northridge
- - Orange
- - San Diego
- - Tustin
- - Walnut Creek
Florida
- - Cocoa Beach
- - Longwood
- - New Port Richey
- - Ocala
- - Saint Cloud
- - Tampa
Arizona
- - Phoenix
Colorado
- - Denver
Georgia
- - Lawrenceville
Hawaii
- - Honolulu
Indiana
- - Avon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
What the finished NCT00286429 record still lists
NCT00286429 is an interventional study that assigns participants to a tested intervention. The registered 390 participants enrollment target is mid-sized for trials with a published cap, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Insulin is the first listed.
NCT00286429 names 20 study sites across 7 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00286429 about?
NCT00286429 is a clinical study titled "Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.". The purpose of this study is to determine the efficacy and safety of alogliptin, once daily (QD), taken in combination with insulin for the treatment of Type 2 Diabetes.
What is the current status of trial NCT00286429?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 390 participants. The study started on 2006-02. Estimated completion is 2007-05.
What conditions does trial NCT00286429 study?
This clinical trial studies the following conditions: Diabetes Mellitus.
What interventions are being tested in trial NCT00286429?
The interventions under investigation include: Insulin (DRUG), Alogliptin and insulin (DRUG).
Who is sponsoring clinical trial NCT00286429?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00286429 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00286429's enrollment target sits among peer trials
390 55th of 208 higher than 154 of 208 other Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
COMPLETED · Phase 3
-
Treatment of Peripheral Neuropathy in Patients With Diabetes
COMPLETED · Phase 3
-
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00397111 · 390 participants
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
- NCT05335928 · 390 participants · Phase 3
Abatacept in Immune Checkpoint Inhibitor Myocarditis
- NCT05445960 · 390 participants · NA
Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery
- NCT05997615 · 390 participants · Phase 1
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia